WO2006038613A1 - Composition orale contenant un anhydride de difructose - Google Patents
Composition orale contenant un anhydride de difructose Download PDFInfo
- Publication number
- WO2006038613A1 WO2006038613A1 PCT/JP2005/018346 JP2005018346W WO2006038613A1 WO 2006038613 A1 WO2006038613 A1 WO 2006038613A1 JP 2005018346 W JP2005018346 W JP 2005018346W WO 2006038613 A1 WO2006038613 A1 WO 2006038613A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sodium
- potassium
- excretion
- dfa
- active ingredient
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 22
- 150000008064 anhydrides Chemical class 0.000 title claims abstract description 14
- 239000011591 potassium Substances 0.000 claims abstract description 49
- 229910052700 potassium Inorganic materials 0.000 claims abstract description 49
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims abstract description 48
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 47
- 239000011734 sodium Substances 0.000 claims abstract description 47
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 47
- 230000029142 excretion Effects 0.000 claims abstract description 37
- 235000013305 food Nutrition 0.000 claims abstract description 20
- 239000004480 active ingredient Substances 0.000 claims abstract description 16
- 230000001737 promoting effect Effects 0.000 claims abstract description 16
- 230000000694 effects Effects 0.000 claims abstract description 9
- 230000002265 prevention Effects 0.000 claims description 13
- 230000002411 adverse Effects 0.000 claims description 6
- 239000003623 enhancer Substances 0.000 claims description 2
- 150000004678 hydrides Chemical class 0.000 claims 2
- 230000035622 drinking Effects 0.000 claims 1
- 230000009931 harmful effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 235000005911 diet Nutrition 0.000 abstract description 5
- 230000037213 diet Effects 0.000 abstract description 4
- 230000003449 preventive effect Effects 0.000 abstract description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 4
- 239000011780 sodium chloride Substances 0.000 abstract 2
- 208000019423 liver disease Diseases 0.000 abstract 1
- 210000003608 fece Anatomy 0.000 description 8
- 210000001035 gastrointestinal tract Anatomy 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 208000017169 kidney disease Diseases 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 235000015598 salt intake Nutrition 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
- 229940029339 inulin Drugs 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 125000000185 sucrose group Chemical group 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- 241000186073 Arthrobacter sp. Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241001672694 Citrus reticulata Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 208000002682 Hyperkalemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- GTDPSWPPOUPBNX-UHFFFAOYSA-N ac1mqpva Chemical compound CC12C(=O)OC(=O)C1(C)C1(C)C2(C)C(=O)OC1=O GTDPSWPPOUPBNX-UHFFFAOYSA-N 0.000 description 1
- -1 acidulants Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 125000000600 disaccharide group Chemical group 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002888 effect on disease Effects 0.000 description 1
- 238000012851 eutrophication Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000013350 formula milk Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- 239000010948 rhodium Substances 0.000 description 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000021127 solid diet Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/105—Aliphatic or alicyclic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/163—Sugars; Polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to an oral composition having a function of promoting sodium and Z or potassium excretion.
- the present invention also relates to an oral composition that has a function of promoting sodium excretion, thereby preventing or ameliorating a disease caused by excessive intake of salt.
- the present invention also relates to an oral composition intended to be useful for restricting sodium and / or potassium intake in patients with kidney disease by having a function of promoting sodium and / or potassium excretion.
- Patent Document 1 discloses a component having a function of excreting dietary sodium mainly composed of polysaccharides outside the body. ing.
- DFA difructose anhydride
- Patent Document 1 JP 2002-87980 A
- Patent Document 2 Japanese Patent Laid-Open No. 2000-270811
- Patent Document 3 Japanese Patent Publication No. 3-5788
- Patent Document 4 Japanese Patent Laid-Open No. 11-43438
- Patent Document 5 Japanese Unexamined Patent Application Publication No. 2003-321371
- Excessive intake of salt is considered to be one of the causes of diseases related to lifestyle-related diseases and their complications, and exacerbations.
- a new composition that improves the adverse effects of excessive intake of salt and prevention improvement The purpose is to provide drugs, food and drink, and feed.
- the present inventors paid attention to the action of promoting sodium excretion via the intestinal tract, and, as a result of continuing research, have the function of promoting excretion of sodium in the body via the intestinal tract. It was found that sodium excretion is promoted via the intestinal tract by the administration of DFA, which has a preventive and ameliorating effect on diseases caused by excessive intake of. Furthermore, the present inventors have paid attention to the effect of promoting potassium excretion via the intestine, and as a result of continuing research, as a result of administration of DFA having a function of promoting potassium excretion via the intestine, It was found that excretion of physical strength rhodium is promoted. That is, the present invention focuses on the function of DFA as an active ingredient that promotes excretion of sodium and Z or potassium in the intestinal tract.
- the main configuration of the present invention that makes use of this function is as follows.
- An oral composition for promoting sodium and Z or potassium excretion characterized by containing difructose anhydride (DFA) as an active ingredient that promotes excretion of sodium and Z or potassium
- An oral composition for improving sodium and Z or potassium overdose prevention characterized by containing difructose anhydride (DFA) as a fraction.
- DFA difructose anhydride
- a sodium, Z or potassium excretion enhancer comprising difructose anhydride (DFA) as an active ingredient that promotes excretion of sodium and Z or potassium.
- DFA difructose anhydride
- DFA difructose anhydride
- DFA difructose anhydride
- a pet feed characterized by containing difructose anhydride (DFA) as an active ingredient that promotes excretion of sodium and Z or potassium.
- DFA difructose anhydride
- DFA difructose anhydride
- the oral composition containing DFA of the present invention promotes in vivo sodium excretion or in vivo potassium excretion via the intestinal tract.
- the DFA referred to in the present invention is an anhydrocyclic disaccharide bonded to two fractoskas at two points.
- Traditionally known to exist in caramel etc. Is produced by fermenting inulin with an inulin-degrading enzyme such as inulin flatrate transferase (EC2.4.1.93) produced by Arthrobacter sp. It can be produced by fermenting with an fructotransferase (EC 2.4.1. 10).
- DFAI DFAIU DFAIII, DFAIV, and DFAV, respectively.
- DFA refers to all of them.
- DFAII I m-D-fructofuranose- ⁇ , 2 ': 2,3 dianhyaride
- DFAIV di-D-fructofuranose-2, 6,2' dianhydride
- the oral composition according to the present invention contains DFA as an active ingredient and can be used as a composition of a pharmaceutical type, a food and drink type, a pet animal feed type, for example, a human or There are no limitations as long as it is a form that can be finally administered orally, such as pharmaceuticals for pet animals, foods and drinks, formula milk, enteral nutrition, health foods and drinks, and pet food additives. Moreover, the content of the active ingredient is not particularly limited.
- DFA or a processed product thereof can be used as it is or in combination with other foods or food ingredients, and can be used according to conventional methods.
- heat stability and acid stability are high, ordinary food processing methods can be applied without any problems.
- Food-type oral compositions containing DFA are not subject to any particular limitation such as powder, granule, paste, liquid or suspension.
- it can be formulated into a health drink using various ingredients commonly used in the manufacture of sweeteners, acidulants, vitamins and other drinks.
- the active ingredient When used as a pharmaceutical type composition, the active ingredient is administered in various forms.
- Examples of the dosage form include oral administration using tablets, capsules, granules, powders, syrups and the like. These various preparations are usually used in the pharmaceutical preparation technical field such as excipients, binders, disintegrants, lubricants, flavoring agents, solubilizing agents, suspension agents, coating agents, etc. as main ingredients in accordance with conventional methods. Can be formulated with known adjuvants wear. The amount used varies depending on symptoms, age, body weight, and dosage form, but is usually 0.5 to 2000 mg / kg body weight per day when administered orally, preferably 1 to 1 for adults.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Birds (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Fodder In General (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Saccharide Compounds (AREA)
- Feed For Specific Animals (AREA)
Abstract
On considère que la prise excessive de chlorure de sodium est l≈aos;un des facteurs de l'apparition et de la dégradation d mladies classées comme maladies liées au style de vie et complicns de celles-ci. Ainsi, l'invention concerne une nouvelle composition pour réduire les effets indésirables de la prise excessde chlorure de sodium de même que des agents préventifs, des reesdes aliments, des boissons et de la nourriture pour animaux domestiques. L'invention entend également accro·re le degramp;mdot;de libert·dans le régime alimentaire des patientssoufrant de troubles hépatiques en favorisant l'excrétion deodm et/ou de potassium. Plus précisément, elle porte sur une compion orale favorisant l'excrétion de sodium et/ou de potassiucontenant de l'anhydride de difructose (DFA) comme ingrédietactif favorisant l'excrétion de sodium et/ou de potassium.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004291541A JP4721684B2 (ja) | 2004-10-04 | 2004-10-04 | ダイフラクトースアンハイドライド含有経口組成物 |
| JP2004-291541 | 2004-10-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2006038613A1 true WO2006038613A1 (fr) | 2006-04-13 |
Family
ID=36142686
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2005/018346 WO2006038613A1 (fr) | 2004-10-04 | 2005-10-04 | Composition orale contenant un anhydride de difructose |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP4721684B2 (fr) |
| WO (1) | WO2006038613A1 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008081795A1 (fr) * | 2006-12-28 | 2008-07-10 | Fancl Corporation | Procédé de fabrication de dfa-iii et extrait végétal ayant une teneur élevée en dfa-iii |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4880508B2 (ja) * | 2007-03-23 | 2012-02-22 | 日本甜菜製糖株式会社 | 免疫グロブリン吸収促進組成物 |
| JP7137368B2 (ja) * | 2017-09-21 | 2022-09-14 | 株式会社ファンケル | ナトリウム排泄促進用及び／又はナトリウム吸収抑制用組成物 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH1143438A (ja) * | 1997-07-29 | 1999-02-16 | Nippon Beet Sugar Mfg Co Ltd | カルシウム吸収亢進組成物 |
| JP2000204042A (ja) * | 1999-01-13 | 2000-07-25 | Nippon Mitsubishi Oil Corp | 環状オリゴ糖 |
| JP2003321371A (ja) * | 2002-04-26 | 2003-11-11 | Fancl Corp | 利尿剤 |
-
2004
- 2004-10-04 JP JP2004291541A patent/JP4721684B2/ja active Active
-
2005
- 2005-10-04 WO PCT/JP2005/018346 patent/WO2006038613A1/fr active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH1143438A (ja) * | 1997-07-29 | 1999-02-16 | Nippon Beet Sugar Mfg Co Ltd | カルシウム吸収亢進組成物 |
| JP2000204042A (ja) * | 1999-01-13 | 2000-07-25 | Nippon Mitsubishi Oil Corp | 環状オリゴ糖 |
| JP2003321371A (ja) * | 2002-04-26 | 2003-11-11 | Fancl Corp | 利尿剤 |
Non-Patent Citations (1)
| Title |
|---|
| HARA HIROSHI.: "Hi Shokasei Torui ni yoru Calcium Kyushu Sokushin Kiko. (Promotive Effects of Nondigestible Saccharides on Calcium Absorbtion)", FOODS & FOOD INGREDIENTS J. JPN., vol. 208, no. 1, 2003, pages 46 - 51, XP002996799 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008081795A1 (fr) * | 2006-12-28 | 2008-07-10 | Fancl Corporation | Procédé de fabrication de dfa-iii et extrait végétal ayant une teneur élevée en dfa-iii |
| JP2008162974A (ja) * | 2006-12-28 | 2008-07-17 | Fancl Corp | Ｄｆａｉｉｉの製造方法及びｄｆａｉｉｉ高含有植物エキス |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2006104103A (ja) | 2006-04-20 |
| JP4721684B2 (ja) | 2011-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4793533B2 (ja) | ポリデキストロースでの免疫系の刺激 | |
| JP3514955B2 (ja) | カルシウム吸収亢進組成物 | |
| JP2011098896A (ja) | 尿酸値低下用組成物 | |
| JP5788715B2 (ja) | 酸素消費量及びエネルギー消費量の低減剤 | |
| WO2006054429A1 (fr) | Composition orale contenant de l’anhydride de difructose | |
| WO2006038613A1 (fr) | Composition orale contenant un anhydride de difructose | |
| US20230201255A1 (en) | Composition comprising cinnamaldehyde and zinc to improve swallowing | |
| JP2010111646A (ja) | 潰瘍性大腸炎治療剤 | |
| WO2009113594A1 (fr) | Agent et aliment pour la prévention/amélioration de troubles gastro-intestinaux fonctionnels | |
| JP4601091B2 (ja) | 環状オリゴ糖 | |
| JPWO2010104175A1 (ja) | 経口用組成物 | |
| JP2002193797A (ja) | インスリン抵抗性改善用組成物 | |
| JP4460234B2 (ja) | ダイエット食品 | |
| JP4778946B2 (ja) | 血中尿酸値低下剤 | |
| JP2009209088A (ja) | アスペルロシドまたはその類縁体を含む筋肉増強剤 | |
| JPH11147828A (ja) | コレステロール及び脂質吸収阻害剤 | |
| JP3248170B2 (ja) | コンドロイチン硫酸蛋白複合体含有食品 | |
| JP3345650B2 (ja) | 高血圧抑制剤 | |
| JP2002255832A (ja) | ミネラル吸収促進剤ならびに貧血改善剤 | |
| JP2004161619A (ja) | 骨形成促進組成物 | |
| JP2004149427A (ja) | ミネラル吸収亢進組成物 | |
| JPWO2008136173A1 (ja) | スチルベン誘導体を有効成分とする脂肪細胞分化抑制剤 | |
| JP6434312B2 (ja) | 組成物、飲食品、内臓脂肪低減剤、血糖値低減剤、内臓脂肪低減用の飲食品、及び血糖値低減用の飲食品 | |
| WO2006080522A1 (fr) | Aliment ou medicament comprenant une bacterie lactique contenant un mineral | |
| JP5463011B2 (ja) | 透析患者用栄養補助剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 05790528 Country of ref document: EP Kind code of ref document: A1 |